METHODS FOR TREATING PULMONARY FIBROTIC DISEASES OR DISORDERS WITH AN ANTI ONCOSTATIN M RECEPTOR BETA ANTIBODY

The disclosure provides methods for treating pulmonary fibrotic disorders, including idiopathic pulmonary fibrosis, by administering to patients therapeutically effective doses and dosing regimens of an anti-OSM receptor β antibody, such as vixarelimab, or anti-OSM receptor β antibody, such as vixar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WILSON, Mark Stephen, RATSIMANDRESY, Rojo A, GALANTER, Joshua Mark, PAN, Lin, YOSHIDA, Kenta
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The disclosure provides methods for treating pulmonary fibrotic disorders, including idiopathic pulmonary fibrosis, by administering to patients therapeutically effective doses and dosing regimens of an anti-OSM receptor β antibody, such as vixarelimab, or anti-OSM receptor β antibody, such as vixarelimab, in combination with an anti-IL-6 antibody or an anti-IL-6 receptor agonisτ, such as tocilizumab. L'invention concerne des méthodes de traitement de troubles fibrotiques pulmonaires, comprenant la fibrose pulmonaire idiopathique, par l'administration à des patients de doses thérapeutiquement efficaces et des posologies d'un anticorps anti-récepteur bêta OSM, tel que le vixarelimab, ou un anticorps anti-récepteur OSM bêta, tel que le vixarelimab, en combinaison avec un anticorps anti-IL-6 ou un agoniste du récepteur anti-IL-6, tel que le tocilizumab.